Last month, the team at Harry and Jeanette Weinberg Cancer Institute at MedStar Franklin Square Medical Center let me know that they are again the first to enroll a patient in a world-wide clinical trial!
Many studies for oncology research are conducted around the world to help the largest number of patients. Estimated enrollment for “Phase III Randomized, Double-Blind Study of Pembrolizumab plus Epacadostat vs Pembrolizumab plus placebo as First-line Treatment in Patients with Metastatic NSCLC expressing high levels of PDL1” (NCT03322540) is more than 580 patients from around the world, at over 160 locations.
Suman Rao, MD, lead PI for the study at MedStar shared that without the commiment of the entire research team, including contracts, regulatory, and pharmacists is what made their team successful. “Special recognition goes to Jean Flack for her commitment to this study. She went the extra length and her persistence was what resulted in making this milestone.”